Peter A. Forsyth, MD

Where You Are:

Peter A. Forsyth, MD

Neuro Oncology



          •  Memorial Sloan-Kettering Cancer Center - Neuro-oncology

          •  Mayo Clinic - Neurology

          •  McMaster University - MD

  • Dalia S, Price S, Forsyth P, Sokol L, Jaglal M. What is the optimal dose of high-dose methotrexate in the initial treatment of primary central nervous system lymphoma?. Leuk Lymphoma. 2015 Feb;56(2):500-502. Pubmedid: 24882264.

  • McKenzie BA, Zemp FJ, Pisklakova A, Narendran A, McFadden G, Lun X, Kenchappa RS, Kurz EU, Forsyth PA. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells. Neurooncol. 2015 Jan. Pubmedid: 25605818.

  • Zemp FJ, McKenzie BA, Lun X, Reilly KM, McFadden G, Yong VW, Forsyth PA. Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus. Cancer Res. 2014 Dec;74(24):7260-7273. Pubmedid: 25336188. Pmcid: PMC4281961.

  • Ahmed KA, Freilich JM, Sloot S, Figura N, Gibney GT, Weber JS, Sarangkasiri S, Chinnaiyan P, Forsyth PA, Etame AB, Rao NG. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neurooncol. 2014 Dec. Pubmedid: 25519302.

  • Anic GM, Madden MH, Nabors LB, Olson JJ, Larocca RV, Thompson ZJ, Pamnani SJ, Forsyth PA, Thompson RC, Egan KM. Reproductive factors and risk of primary brain tumors in women. J Neurooncol. 2014 Jun;118(2):297-304. Pubmedid: 24700240. Pmcid: PMC4048769.

  • Dalia S, Forsyth P, Chavez J, Price S, Shah B, Bello C, Sokol L, Pan E, Sotomayor E, Lee JH, Fisher K, Jaglal M. Primary B-cell CNS lymphoma clinicopathologic and treatment outcomes in 89 patients from a single tertiary care center. Int J Hematol. 2014 Apr;99(4):450-456. Pubmedid: 24584873.

  • Weng M, Wei G, Ma M, Chu B, Qin Y, Zhang M, Lun X, McFadden G, Forsyth P, Yang Y, Quan Z. Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo. Mol Cancer. 2014 Apr;13(1):82. Pubmedid: 24725816.

  • Forsyth PA, Krishna N, Lawn S, Valadez JG, Qu X, Fenstermacher DA, Fournier M, Potthast L, Chinnaiyan P, Gibney GT, Zeinieh M, Barker PA, Carter BD, Cooper MK, Kenchappa RS. p75 neurotrophin receptor cleavage by ?- and ?-secretases is required for neurotrophin-mediated proliferation of brain tumor-initiating cells. J Biol Chem. 2014 Mar;289(12):8067-8085. Pubmedid: 24519935. Pmcid: PMC3961639.

  • Ogbomo H, Zemp FJ, Lun X, Zhang J, Stack D, Rahman MM, McFadden G, Mody CH, Forsyth PA. Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo. PLoS One. 2014 Feb;8(6):e66825. Pubmedid: 23762498. Pmcid: PMC3677932.

  • Sarkar S, D?ring A, Zemp FJ, Silva C, Lun X, Wang X, Kelly J, Hader W, Hamilton M, Mercier P, Dunn JF, Kinniburgh D, van Rooijen N, Robbins S, Forsyth P, Cairncross G, Weiss S, Yong VW. Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells. Nat Neurosci. 2014 Jan;17(1):46-55. Pubmedid: 24316889.

  • Zemp FJ, McKenzie BA, Lun X, Maxwell L, Reilly KM, McFadden G, Yong VW, Forsyth PA. Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon. PLoS One. 2014 Jan;8(6):e65801. Pubmedid: 23762429. Pmcid: PMC3675064.

  • Anic GM, Madden MH, Thompson RC, Nabors LB, Olson JJ, Larocca RV, Browning JE, Brockman JD, Forsyth PA, Egan KM. Toenail iron, genetic determinants of iron status, and the risk of glioma. Cancer Causes Control. 2013 Dec;24(12):2051-2058. Pubmedid: 23996192. Pmcid: PMC3823695.

  • Lun X, Ruan Y, Jayanthan A, Liu DJ, Singh A, Trippett T, Bell J, Forsyth P, Johnston RN, Narendran A. Double-deleted vaccinia virus in virotherapy for refractory and metastatic pediatric solid tumors. Mol Oncol. 2013 Oct;7(5):944-954. Pubmedid: 23816608.

  • Kenchappa RS, Tran N, Rao NG, Smalley KS, Gibney GT, Sondak VK, Forsyth PA. Novel treatments for melanoma brain metastases. Cancer Control. 2013 Oct;20(4):298-306. Pubmedid: 24077406.

  • Zemp FJ, Lun X, McKenzie BA, Zhou H, Maxwell L, Sun B, Kelly JJ, Stechishin O, Luchman A, Weiss S, Cairncross JG, Hamilton MG, Rabinovich BA, Rahman MM, Mohamed MR, Smallwood S, Senger DL, Bell J, McFadden G, Forsyth PA. Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin. Neurooncol. 2013 Jul;15(7):904-920. Pubmedid: 23585629. Pmcid: PMC3688014.

  • Singh A, Lun X, Jayanthan A, Obaid H, Ruan Y, Strother D, Chi SN, Smith A, Forsyth P, Narendran A. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib. Mol Oncol. 2013 Jun;7(3):497-512. Pubmedid: 23375777.

  • Jenne CN, Wong CH, Zemp FJ, McDonald B, Rahman MM, Forsyth PA, McFadden G, Kubes P. Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps. Cell Host Microbe. 2013 Feb;13(2):169-180. Pubmedid: 23414757.

  • Chinnaiyan P, Kensicki E, Bloom G, Prabhu A, Sarcar B, Kahali S, Eschrich S, Qu X, Forsyth P, Gillies R. The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. Cancer Res. 2012 Nov;72(22):5878-5888. Pubmedid: 23026133.

  • Anic GM, Thompson RC, Burton Nabors L, Olson JJ, Browning JE, Madden MH, Reed Murtagh F, Forsyth PA, Egan KM. An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome. Cancer Causes Control. 2012 Sep;23(9):1443-1449. Pubmedid: 22740028. Pmcid: PMC3563063.

  • Morris DG, Feng X, Difrancesco LM, Fonseca K, Forsyth PA, Paterson AH, Coffey MC, Thompson B. REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin?) in patients with advanced solid tumors. Invest New Drugs. 2012 Aug;31(3):696-706. Pubmedid: 22886613.

  • Gibney GT, Forsyth PA, Sondak VK. Melanoma in the brain: biology and therapeutic options. Melanoma Res. 2012 Jun;22(3):177-183. Pubmedid: 22495668.

  • Rold?n G, Chan J, Eliasziw M, Cairncross JG, Forsyth PA. Leptomeningeal disease in oligodendroglial tumors: a population-based study. J Neurooncol. 2012 Jan;104(3):811-815. Pubmedid: 21373968. Pmcid: PMC3170119.

  • Couldwell WT, Surnock AA, Tobia AJ, Cabana BE, Stillerman CB, Forsyth PA, Appley AJ, Spence AM, Hinton DR, Chen TC. A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas. Cancer. 2011 Nov;117(21):4905-4915. Pubmedid: 21456013.

  • Ogbomo H, Cinatl J, Mody CH, Forsyth PA. Immunotherapy in gliomas: limitations and potential of natural killer (NK) cell therapy. Trends Mol Med. 2011 Aug;17(8):433-441. Pubmedid: 21507717.

  • Forsyth PA, Hauert C. Public goods games with reward in finite populations. J Math Biol. 2011 Jul;63(1):109-123. Pubmedid: 20865261.

  • Kim M, Garant KA, zur Nieden NI, Alain T, Loken SD, Urbanski SJ, Forsyth PA, Rancourt DE, Lee PW, Johnston RN. Attenuated reovirus displays oncolysis with reduced host toxicity. Br J Cancer. 2011 Jan;104(2):290-299. Pubmedid: 21179029. Pmcid: PMC3031901.

  • Lun X, Chan J, Zhou H, Sun B, Kelly JJ, Stechishin OO, Bell JC, Parato K, Hu K, Vaillant D, Wang J, Liu TC, Breitbach C, Kirn D, Senger DL, Forsyth PA. Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. Mol Ther. 2010 Nov;18(11):1927-1936. Pubmedid: 20808290. Pmcid: PMC2990519.

  • Rodrigues JC, Gonzalez GC, Zhang L, Ibrahim G, Kelly JJ, Gustafson MP, Lin Y, Dietz AB, Forsyth PA, Yong VW, Parney IF. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol. 2010 Jul;12(4):351-365. Pubmedid: 20308313. Pmcid: PMC2940603.

  • Perry JR, B?langer K, Mason WP, Fulton D, Kavan P, Easaw J, Shields C, Kirby S, Macdonald DR, Eisenstat DD, Thiessen B, Forsyth P, Pouliot JF. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010 Apr;28(12):2051-2057. Pubmedid: 20308655.

  • Lwu S, Hamilton MG, Forsyth PA, Cairncross JG, Parney IF. Use of peri-operative anti-epileptic drugs in patients with newly diagnosed high grade malignant glioma: a single center experience. J Neurooncol. 2010 Feb;96(3):403-408. Pubmedid: 19669097.

  • Lun X, Alain T, Zemp FJ, Zhou H, Rahman MM, Hamilton MG, McFadden G, Bell J, Senger DL, Forsyth PA. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. Cancer Res. 2010 Jan;70(2):598-608. Pubmedid: 20068158.

  • Alain T, Muzik H, Otsuka S, Chan S, Magliocco T, Diaz R, Forsyth PA, Morris D, Bebb G. Susceptibility of mantle cell lymphomas to reovirus oncolysis. Leuk Res. 2010 Jan;34(1):100-108. Pubmedid: 19651440.

  • Thiessen B, Stewart C, Tsao M, Kamel-Reid S, Schaiquevich P, Mason W, Easaw J, Belanger K, Forsyth P, McIntosh L, Eisenhauer E. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol. 2010 Jan;65(2):353-361. Pubmedid: 19499221.

  • Rold?n GB, Scott JN, McIntyre JB, Dharmawardene M, de Robles PA, Magliocco AM, Yan ES, Parney IF, Forsyth PA, Cairncross JG, Hamilton MG, Easaw JC. Population-based study of pseudoprogression after chemoradiotherapy in GBM. Can J Neurol Sci. 2009 Sep;36(5):617-622. Pubmedid: 19831132.

  • Delaney L, Chambers C, Rold?n G, De Robles P, Cairncross G, Forsyth P, Easaw J. A feasibility study to assess the integration of a pharmacist into neurooncology clinic. J Oncol Pharm Pract. 2009 Jun;15(2):79-85. Pubmedid: 19036905.

  • Lun XQ, Jang JH, Tang N, Deng H, Head R, Bell JC, Stojdl DF, Nutt CL, Senger DL, Forsyth PA, McCart JA. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res. 2009 Apr;15(8):2777-2788. Pubmedid: 19351762.

  • Wang L, Rahn JJ, Lun X, Sun B, Kelly JJ, Weiss S, Robbins SM, Forsyth PA, Senger DL. Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor. PLoS Biol. 2008 Nov;6(11):e289. Pubmedid: 19067488. Pmcid: PMC2586378.

  • de Robles P, McIntyre J, Kalra S, Rold?n G, Cairncross G, Forsyth P, Magliocco T, Hamilton M, Easaw J. Methylation status of MGMT gene promoter in meningiomas. Cancer Genet Cytogenet. 2008 Nov;187(1):25-27. Pubmedid: 18992637.

  • Mohile NA, Forsyth P, Stewart D, Raizer JJ, Paleologos N, Kewalramani T, Louis DN, Cairncross JG, Abrey LE. A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis. J Neurooncol. 2008 Sep;89(2):187-193. Pubmedid: 18458821.

  • Sijben AE, McIntyre JB, Rold?n GB, Easaw JC, Yan E, Forsyth PA, Parney IF, Magliocco AM, Bernsen H, Cairncross JG. Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neurooncol. 2008 Aug;89(1):97-103. Pubmedid: 18398569.

  • Rold?n G, Brasher P, Vecil G, Senger D, Rewcastle B, Cairncross G, Forsyth P, Hamilton M. Population-based study of medulloblastoma: outcomes in Alberta from 1975 to 1996. Can J Neurol Sci. 2008 May;35(2):210-215. Pubmedid: 18574936.

  • Rold?n G, Scott J, George D, Parney I, Easaw J, Cairncross G, Forsyth P, Yan E. Leptomeningeal disease from oligodendroglioma: clinical and molecular analysis. Can J Neurol Sci. 2008 May;35(2):204-209. Pubmedid: 18574935.

  • Barrett JW, Alston LR, Wang F, Stanford MM, Gilbert PA, Gao X, Jimenez J, Villeneuve D, Forsyth P, McFadden G. Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells. J Neurovirol. 2007 Dec;13(6):549-560. Pubmedid: 18097886.

  • Alain T, Wong JF, Endersby R, Urbanski SJ, Lee PW, Muruve DA, Johnston RN, Forsyth PA, Beck PL. Reovirus decreases azoxymethane-induced aberrant crypt foci and colon cancer in a rodent model. Cancer Gene Ther. 2007 Oct;14(10):867-872. Pubmedid: 17627293.

  • Lun XQ, Zhou H, Alain T, Sun B, Wang L, Barrett JW, Stanford MM, McFadden G, Bell J, Senger DL, Forsyth PA. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res. 2007 Sep;67(18):8818-8827. Pubmedid: 17875723.

  • Mauer M, Stupp R, Taphoorn MJ, Coens C, Osoba D, Marosi C, Wong R, de Witte O, Cairncross JG, Efficace F, Mirimanoff RO, Forsyth P, van den Bent MJ, Weller M, Bottomley A. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. Br J Cancer. 2007 Aug;97(3):302-307. Pubmedid: 17609661. Pmcid: PMC2360328.

  • Alain T, Kim TS, Lun X, Liacini A, Schiff LA, Senger DL, Forsyth PA. Proteolytic disassembly is a critical determinant for reovirus oncolysis. Mol Ther. 2007 Aug;15(8):1512-1521. Pubmedid: 17519890.

  • Kim M, Egan C, Alain T, Urbanski SJ, Lee PW, Forsyth PA, Johnston RN. Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells. Oncogene. 2007 Jun;26(28):4124-4134. Pubmedid: 17213803.

  • Robertson KE, Forsyth PD, Batstone PJ, Levison DA, Goodlad JR. Kikuchi's disease displaying a t(2:16) chromosomal translocation. J Clin Pathol. 2007 Apr;60(4):433-435. Pubmedid: 17405981. Pmcid: PMC2001119.

  • Power AT, Wang J, Falls TJ, Paterson JM, Parato KA, Lichty BD, Stojdl DF, Forsyth PA, Atkins H, Bell JC. Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther. 2007 Jan;15(1):123-130. Pubmedid: 17164783.

  • Alain T, Kim M, Johnston RN, Urbanski S, Kossakowska AE, Forsyth PA, Lee PW. The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro. Brit J Cancer. 2006 Oct;95(8):1020-1027. Pubmedid: 17047650. Pmcid: PMC2360720.

  • Tang P, Roldan G, Brasher PM, Fulton D, Roa W, Murtha A, Cairncross JG, Forsyth PA. A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neurooncol. 2006 Jul;78(3):311-316. Pubmedid: 16710748.

  • Levin VA, Phuphanich S, Yung WK, Forsyth PA, Maestro RD, Perry JR, Fuller GN, Baillet M. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol. 2006 Jul;78(3):295-302. Pubmedid: 16636750.

  • Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D, Finlay JL, Gardner S, Peterson K, Hu W, Swinnen L, Bayer R, Forsyth P, Stewart D, Smith AM, Macdonald DR, Weaver S, Ramsay DA, Nimer SD, DeAngelis LM, Cairncross JG. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. Neurooncol. 2006 Apr;8(2):183-188. Pubmedid: 16524945. Pmcid: PMC1871935.

  • Moss EL, Simpson JS, Pelletier G, Forsyth P. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psychooncology. 2006 Mar;15(3):259-267. Pubmedid: 16041840.

  • Taphoorn MJ, Stupp R, Coens C, Osoba D, Kortmann R, van den Bent MJ, Mason W, Mirimanoff RO, Baumert BG, Eisenhauer E, Forsyth P, Bottomley A. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol. 2005 Dec;6(12):937-944. Pubmedid: 16321761.

  • Thirukkumaran CM, Luider JM, Stewart DA, Alain T, Russell JA, Auer IA, Forsyth P, Morris DG. Biological purging of breast cancer cell lines using a replication-competent oncolytic virus in human stem cell autografts. Bone Marrow Transplant. 2005 Jun;35(11):1055-1064. Pubmedid: 15821774.

  • Kirby S, Gertler SZ, Mason W, Watling C, Forsyth P, Aniagolu J, Stagg R, Wright M, Powers J, Eisenhauer EA. Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials Group. Neuro Oncol. 2005 Apr;7(2):183-188. Pubmedid: 15831236. Pmcid: PMC1871890.

  • Yang WQ, Lun X, Palmer CA, Wilcox ME, Muzik H, Shi ZQ, Dyck R, Coffey M, Thompson B, Hamilton M, Nishikawa SG, Brasher PM, Fonseca K, George D, Rewcastle NB, Johnston RN, Stewart D, Lee PW, Senger DL, Forsyth PA. Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates. Clin Cancer Res. 2004 Dec;10(24):8561-8576. Pubmedid: 15623640.

  • Yang WQ, Senger DL, Lun XQ, Muzik H, Shi ZQ, Dyck RH, Norman K, Brasher PM, Rewcastle NB, George D, Stewart D, Lee PW, Forsyth PA. Reovirus as an experimental therapeutic for brain and leptomeningeal metastases from breast cancer. Gene Ther. 2004 Nov;11(21):1579-1589. Pubmedid: 15372068.

  • Megyesi JF, Kachur E, Lee DH, Zlatescu MC, Betensky RA, Forsyth PA, Okada Y, Sasaki H, Mizoguchi M, Louis DN, Cairncross JG. Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res. 2004 Jul;10(13):4303-4306. Pubmedid: 15240515.

  • Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, Fisher B, Fulton D, Gulavita S, Hao C, Husain S, Murtha A, Petruk K, Stewart D, Tai P, Urtasun R, Cairncross JG, Forsyth P. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004 May;22(9):1583-1588. Pubmedid: 15051755.

  • Fallon KB, Palmer CA, Roth KA, Nabors LB, Wang W, Carpenter M, Banerjee R, Forsyth P, Rich K, Perry A. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol. 2004 Apr;63(4):314-322. Pubmedid: 15099021.

  • Vieyra D, Senger DL, Toyama T, Muzik H, Brasher PM, Johnston RN, Riabowol K, Forsyth PA, Toyam T. Altered subcellular localization and low frequency of mutations of ING1 in human brain tumors. Clin Cancer Res. 2003 Dec;9(16 Pt 1):5952-5961. Pubmedid: 14676120.

  • B?langer K, MacDonald D, Cairncross G, Gertler S, Forsyth P, Burdette-Radoux S, Bergeron J, Souli?res D, Ludwin S, Wainman N, Eisenhauer E. A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma. Invest New Drugs. 2003 Nov;21(4):473-480. Pubmedid: 14586216.

  • Abrey LE, Childs BH, Paleologos N, Kaminer L, Rosenfeld S, Salzman D, Finlay JL, Gardner S, Peterson K, Hu W, Swinnen L, Bayer R, Forsyth P, Stewart D, Smith AM, Macdonald DR, Weaver S, Ramsey DA, Nimer SD, DeAngelis LM, Cairncross JG. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma. J Neurooncol. 2003 Nov;65(2):127-134. Pubmedid: 14686732.

  • Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003 Nov;21(22):4151-4156. Pubmedid: 14615443.

  • Yang WQ, Senger D, Muzik H, Shi ZQ, Johnson D, Brasher PM, Rewcastle NB, Hamilton M, Rutka J, Wolff J, Wetmore C, Curran T, Lee PW, Forsyth PA. Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma. Cancer Res. 2003 Jun;63(12):3162-3172. Pubmedid: 12810644.

  • Forsyth PA, Weaver S, Fulton D, Brasher PM, Sutherland G, Stewart D, Hagen NA, Barnes P, Cairncross JG, DeAngelis LM. Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci. 2003 May;30(2):106-112. Pubmedid: 12774949.

  • Senger D, Cairncross JG, Forsyth PA. Long-term survivors of glioblastoma: statistical aberration or important unrecognized molecular subtype?. Cancer J. 2003 May-June;9(3):214-221. Pubmedid: 12952306.

  • Cheng T, Forsyth P, Chaudhry A, Morris D, Gl?ck S, Russell JA, Stewart DA. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant. 2003 Apr;31(8):679-685. Pubmedid: 12692608.

  • Nuttall RK, Pennington CJ, Taplin J, Wheal A, Yong VW, Forsyth PA, Edwards DR. Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol Cancer Res. 2003 Mar;1(5):333-345. Pubmedid: 12651907.

  • Zia MI, Forsyth P, Chaudhry A, Russell J, Stewart DA. Possible benefits of high-dose chemotherapy and autologous stem cell transplantation for adults with recurrent medulloblastoma. Bone Marrow Transplant. 2002 Nov;30(9):565-569. Pubmedid: 12407430.

  • Burton EC, Lamborn KR, Feuerstein BG, Prados M, Scott J, Forsyth P, Passe S, Jenkins RB, Aldape KD. Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res. 2002 Nov;62(21):6205-6210. Pubmedid: 12414648.

  • Burton EC, Lamborn KR, Forsyth P, Scott J, O'Campo J, Uyehara-Lock J, Prados M, Berger M, Passe S, Uhm J, O'Neill BP, Jenkins RB, Aldape KD. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. Clin Cancer Res. 2002 Jan;8(1):180-187. Pubmedid: 11801556.

  • Forsyth PA, Stewart DA. Oligodendrogliomas: the Achilles' heel of malignant gliomas. Can J Neurol Sci. 2001 Aug;28(3):187-188. Pubmedid: 11513335.

  • Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci. 2001 Jul;2(7):502-511. Pubmedid: 11433375.

  • Groft LL, Muzik H, Rewcastle NB, Johnston RN, Kn?uper V, Lafleur MA, Forsyth PA, Edwards DR. Differential expression and localization of TIMP-1 and TIMP-4 in human gliomas. Br J Cancer. 2001 Jul;85(1):55-63. Pubmedid: 11437402. Pmcid: PMC2363922.

  • Wilcox ME, Yang W, Senger D, Rewcastle NB, Morris DG, Brasher PM, Shi ZQ, Johnston RN, Nishikawa S, Lee PW, Forsyth PA. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst. 2001 Jun;93(12):903-912. Pubmedid: 11416111.

  • Lafleur MA, Forsyth PA, Atkinson SJ, Murphy G, Edwards DR. Perivascular cells regulate endothelial membrane type-1 matrix metalloproteinase activity. Biochem Bioph Res Co. 2001 Mar;282(2):463-473. Pubmedid: 11401482.

  • Hill MD, Czechowsky D, Forsyth P, Perry JR. Heritable bone disease and stroke due to vertebral artery dissection. Cerebrovasc Dis. 2001;12(1):73-74. Pubmedid: 11484738.

  • Raithatha SA, Muzik H, Muzik H, Rewcastle NB, Johnston RN, Edwards DR, Forsyth PA. Localization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas. Neuro Oncol. 2000 Jul;2(3):145-150. Pubmedid: 11302334. Pmcid: PMC1920497.

  • Cairncross G, Swinnen L, Bayer R, Rosenfeld S, Salzman D, Paleologos N, Kaminer L, Forsyth P, Stewart D, Peterson K, Hu W, Macdonald D, Ramsay D, Smith A. Myeloablative chemotherapy for recurrent aggressive oligodendroglioma. Neuro Oncol. 2000 Apr;2(2):114-119. Pubmedid: 11303620. Pmcid: PMC1919513.

  • Gertler SZ, MacDonald D, Goodyear M, Forsyth P, Stewart DJ, Belanger K, Perry J, Fulton D, Steward W, Wainman N, Seymour L. NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94). Ann Oncol. 2000 Mar;11(3):315-318. Pubmedid: 10811498.

  • Toyama T, Iwase H, Watson P, Muzik H, Saettler E, Magliocco A, DiFrancesco L, Forsyth P, Garkavtsev I, Kobayashi S, Riabowol K. Suppression of ING1 expression in sporadic breast cancer. Oncogene. 1999 Sep;18(37):5187-5193. Pubmedid: 10498868.

  • Scott JN, Rewcastle NB, Brasher PM, Fulton D, MacKinnon JA, Hamilton M, Cairncross JG, Forsyth P. Which glioblastoma multiforme patient will become a long-term survivor? A population-based study. Ann Neurol. 1999 Aug;46(2):183-188. Pubmedid: 10443883.

  • Forsyth PA, Wong H, Laing TD, Rewcastle NB, Morris DG, Muzik H, Leco KJ, Johnston RN, Brasher PM, Sutherland G, Edwards DR. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer. 1999 Apr;79(11-12):1828-1835. Pubmedid: 10206300. Pmcid: PMC2362801.

  • Hao D, DiFrancesco LM, Brasher PM, deMetz C, Fulton DS, DeAngelis LM, Forsyth PA. Is primary CNS lymphoma really becoming more common? A population-based study of incidence, clinicopathological features and outcomes in Alberta from 1975 to 1996. Ann Oncol. 1999 Jan;10(1):65-70. Pubmedid: 10076724.

  • Giannini C, Scheithauer BW, Burger PC, Christensen MR, Wollan PC, Sebo TJ, Forsyth PA, Hayostek CJ. Cellular proliferation in pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol. 1999 Jan;58(1):46-53. Pubmedid: 10068313.

  • Scott JN, Rewcastle NB, Brasher PM, Fulton D, Hagen NA, MacKinnon JA, Sutherland G, Cairncross JG, Forsyth P. Long-term glioblastoma multiforme survivors: a population-based study. Can J Neurol Sci. 1998 Aug;25(3):197-201. Pubmedid: 9706720.

  • Wallace C, Fletcher W, MacRae E, Forsyth P. Malignant suprasellar gliomas: 4 case reports. Can Assoc Radiol J. 1998 Apr;49(2):124-128. Pubmedid: 9561015.

  • Yong VW, Krekoski CA, Forsyth PA, Bell R, Edwards DR. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci. 1998 Feb;21(2):75-80. Pubmedid: 9498303.

  • Forsyth PA, Laing TD, Gibson AW, Rewcastle NB, Brasher P, Sutherland G, Johnston RN, Edwards DR. High levels of gelatinase-B and active gelatinase-A in metastatic glioblastoma. J Neurooncol. 1998 Jan;36(1):21-29. Pubmedid: 9525822.

  • Forsyth PA, Balmaceda C, Peterson K, Seidman AD, Brasher P, DeAngelis LM. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol. 1997 Oct;35(1):47-53. Pubmedid: 9266440.

  • Forsyth PA, Dalmau J, Graus F, Cwik V, Rosenblum MK, Posner JB. Motor neuron syndromes in cancer patients. Ann Neurol. 1997 Jun;41(6):722-730. Pubmedid: 9189033.

  • Forsyth PA, Petrov E, Mahallati H, Cairncross JG, Brasher P, MacRae ME, Hagen NA, Barnes P, Sevick RJ. Prospective study of postoperative magnetic resonance imaging in patients with malignant gliomas. J Clin Oncol. 1997 May;15(5):2076-2081. Pubmedid: 9164220.

  • Wallace CJ, Forsyth PA, Edwards DR. Lymph node metastases from glioblastoma multiforme. AJNR Am J Neuroradiol. 1996 Nov-Dec;17(10):1929-1931. Pubmedid: 8933881.

  • Meckling S, Dold O, Forsyth PA, Brasher P, Hagen NA. Malignant supratentorial glioma in the elderly: is radiotherapy useful?. Neurology. 1996 Oct;47(4):901-905. Pubmedid: 8857716.

  • Forsyth PA, Cairncross JG. Chemotherapy for malignant gliomas. Baillieres Clin Neurol. 1996 Jun;5(2):371-393. Pubmedid: 8781278.

  • Macdonald D, Cairncross G, Stewart D, Forsyth P, Sawka C, Wainman N, Eisenhauer E. Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group. Ann Oncol. 1996 Feb;7(2):205-207. Pubmedid: 8777179.

  • Fulton D, Urtasun R, Forsyth P. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol. 1996 Feb;27(2):149-155. Pubmedid: 8699237.

  • Forsyth PA, Cairncross JG. Treatment of malignant glioma in adults. Curr Opin Neurol. 1995 Dec;8(6):414-418. Pubmedid: 8845922.

  • Seidman AD, Reichman BS, Crown JP, Yao TJ, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol. 1995 May;13(5):1152-1159. Pubmedid: 7537798.

  • Forsyth PA, Kelly PJ, Cascino TL, Scheithauer BW, Shaw EG, Dinapoli RP, Atkinson EJ. Radiation necrosis or glioma recurrence: is computer-assisted stereotactic biopsy useful?. J Neurosurg. 1995 Mar;82(3):436-444. Pubmedid: 7861222.

  • Caviness JN, Forsyth PA, Layton DD, McPhee TJ. The movement disorder of adult opsoclonus. Mov Disord. 1995 Jan;10(1):22-27. Pubmedid: 7885352.

  • Mitchell A, Scheithauer BW, Unni KK, Forsyth PJ, Wold LE, McGivney DJ. Chordoma and chondroid neoplasms of the spheno-occiput. An immunohistochemical study of 41 cases with prognostic and nosologic implications. Cancer. 1993 Nov;72(10):2943-2949. Pubmedid: 7693324.

  • Forsyth PA, Posner JB. Headaches in patients with brain tumors: a study of 111 patients. Neurology. 1993 Sep;43(9):1678-1683. Pubmedid: 8414011.

  • Forsyth PA, Shaw EG, Scheithauer BW, O'Fallon JR, Layton DD, Katzmann JA. Supratentorial pilocytic astrocytomas. A clinicopathologic, prognostic, and flow cytometric study of 51 patients. Cancer. 1993 Aug;72(4):1335-1342. Pubmedid: 8339223.

  • Tomlinson FH, Scheithauer BW, Forsythe PA, Unni KK, Meyer FB. Sarcomatous transformation in cranial chordoma. Neurosurgery. 1992 Jul;31(1):13-18. Pubmedid: 1641093.

  • Hook CC, Kimmel DW, Kvols LK, Scheithauer BW, Forsyth PA, Rubin J, Moertel CG, Rodriguez M. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol. 1992 Mar;31(3):262-267. Pubmedid: 1637134.

  • Collins SM, Conover KL, Forsyth PA, Weingarten HP. Endogenous cholecystokinin and intestinal satiety. Am J Physiol. 1985 Dec;249(6 Pt 2):R667-R671. Pubmedid: 4073287.

  • Forsyth PA, Weingarten HP, Collins SM. Role of oropharyngeal stimulation in cholecystokinin-induced satiety in the sham feeding rat. Physiol Behav. 1985 Oct;35(4):539-543. Pubmedid: 4070427.

  • Collins S, Walker D, Forsyth P, Belbeck L. The effects of proglumide on cholecystokinin-, bombesin-, and glucagon-induced satiety in the rat. Life Sci. 1983 May;32(19):2223-2229. Pubmedid: 6843294.

Dr. Peter Forsyth is chairman of the Neuro-Oncology Program at Moffitt Cancer Center and professor of oncology at the University of South Florida.  An internationally recognized neuro-oncology physician-scientist, Dr. Forsyth joined Moffitt in 2011 after more than a decade with the Tom Baker Cancer Centre at the University of Calgary in Canada, where he was a professor of oncology and neurosciences, as well as associate director of research.

Dr. Forsyth has a strong interest in malignant, invasive glioma brain tumors.  He is currently investigating several tumor-inhibiting agents in Phase I clinical trials.   One of his first priorities at Moffitt is to develop a neural tumor stem cell lab to expand research opportunities in novel therapeutic cancer-fighting drugs.  Currently, he has 10 active grants funding his studies.

Dr. Forsyth received his medical degree at McMasters University in Ontario, completed a neurology residency at the Mayo Clinic and then a fellowship at Memorial Sloan-Kettering Cancer Center.  Before joining Moffitt, he was interim director of the Southern Alberta Cancer Research Institute.  Dr. Forsyth is the recipient of numerous awards and honors, including receiving the Canadian Cancer Society Award of Excellence in Medicine & Health twice.  In 2006, he was a guest professor at Second Hospital of Shangdong Province in China.




TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions